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Abstract
Objectives
1) To use data-driven method to examine clinical codes (risk factors) of a medical condition
in primary care electronic health records (EHRs) that can accurately predict a diagnosis of
the condition in secondary care EHRs. 2) To develop and validate a disease phenotyping
algorithm for rheumatoid arthritis using primary care EHRs.
Methods
This study linked routine primary and secondary care EHRs in Wales, UK. A machine learn-
ing based scheme was used to identify patients with rheumatoid arthritis from primary care
EHRs via the following steps: i) selection of variables by comparing relative frequencies of
Read codes in the primary care dataset associated with disease case compared to non-dis-
ease control (disease/non-disease based on the secondary care diagnosis); ii) reduction of
predictors/associated variables using a Random Forest method, iii) induction of decision
rules from decision tree model. The proposed method was then extensively validated on an
independent dataset, and compared for performance with two existing deterministic algo-
rithms for RA which had been developed using expert clinical knowledge.
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Results
Primary care EHRs were available for 2,238,360 patients over the age of 16 and of these
20,667 were also linked in the secondary care rheumatology clinical system. In the linked
dataset, 900 predictors (out of a total of 43,100 variables) in the primary care record were
discovered more frequently in those with versus those without RA. These variables were
reduced to 37 groups of related clinical codes, which were used to develop a decision tree
model. The final algorithm identified 8 predictors related to diagnostic codes for RA, medica-
tion codes, such as those for disease modifying anti-rheumatic drugs, and absence of alter-
native diagnoses such as psoriatic arthritis. The proposed data-driven method performed
as well as the expert clinical knowledge based methods.
Conclusion
Data-driven scheme, such as ensemble machine learning methods, has the potential of
identifying the most informative predictors in a cost-effective and rapid way to accurately
and reliably classify rheumatoid arthritis or other complex medical conditions in primary
care EHRs.
Background
Rheumatoid arthritis (RA) is the most common chronic inflammatory arthritis worldwide. It
affects approximately 1% of the population in countries like the UK [1] and USA [2], with sig-
nificant morbidity and increased mortality. Most RA clinical trials capture relatively short-
term data in small numbers of patients, while longer trials are costly and time-consuming, with
difficulty maintaining the levels of follow up required to evaluate the important long-term out-
comes in this chronic, life-long disease. Emerging studies have shown that patient recruitment
for clinical trials and follow up from trials could be significantly improved by use of electronic
health records [3][4][5][6]. But a key requirement is the accurate and reliable identification of
patients who satisfy the RA criteria from electronic health records.
Indeed, in this age of big data, large quantities of real time data from national and regional
population datasets can be accessed and utilised to gain knowledge on the entire population
rather than extrapolating from a single sample. It is now possible to examine a patient’s jour-
ney through the healthcare system by linking their electronic health records [7,8]. One can
examine information on first symptoms, tests/results, referrals, diagnosis, and prescriptions
for all patients with a condition in the region or country, providing an unparalleled opportu-
nity to study disease in a real world setting. This offers the chance for real time surveillance of
disease history, co-morbidities and long term treatment effects in patients with chronic dis-
eases, such as RA. However, since the introduction of biologic therapies, patients with RA are
generally diagnosed and managed in specialist rheumatology centres, with relatively limited
input from primary care physicians. As such, secondary care electronic health records contain
more robust RA-related diagnostic data than primary care records, but these records are
sparse, cover far smaller patient numbers, often contain only severe active disease and are not
easily available. This leads to only identifying patients with RA in that specific rheumatology
secondary care setting, thereby introducing bias and limiting generalizability. In contrast,
primary care data is more widely available containing a much broader spectrum of patient
care codes including details of a patient’s diagnoses, medications, managements and health
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outcomes and information on demographic variables and co-morbidies. But, in primary care
EHRs, the non-specific diagnosis of ‘arthritis’ can be used for people who have other condi-
tions like osteoarthritis, ankylosing spondylitis or non-specific joint pain [9] meaning that
some conditions may appear under-reported in primary care while others over-reported. So
accurately and reliably identifying patients with RA from primary care database remains chal-
lenging, and usually requires a combination of evidence from diagnosis, medication, treat-
ment and investigation codes [10,11]. Existing algorithms to identify RA from primary care
records are based on manual selection of the most relevant codes [12]. Thomas et al ‘s method
[12] is based on codes chosen manually by clinical experts, while the other method [13] is
based on the codes used by the Quality and Outcomes Framework (QOF), a pay for perfor-
mance scheme in which a standardised set of clinician-selected codes is used to determine the
prevalence of a condition (in this case RA) in a practice. However, the methodology of manual
selection of relevant codes based on expert knowledge is very subjective and depends on the
health care system of the area and what clinicians (often secondary care physicians) think
should be found in the primary care record.
An alternative is to use secondary care diagnosis as a gold standard and examine which
health-related codes in the primary care dataset are predictive of a secondary care diagnosis.
That leads to patterns found in the primary care records can be used to predict the presence or
absence of the RA in secondary care specialist data. This means RA can be reliably identified
using primary care records in the absence of access to secondary care specialist records. But
identifying these patterns is not straightforward, because the criteria which characterise the RA
are buried within complex hierarchical terminology structures across multiple data points in
the electronic health records of a patient, such as the Read codes (5 bytes, Version 3)[14] devel-
oped by the National Health Service of the United Kingdom (NHS), or the SNOMED CT
(Systematized Nomenclature of Medicine Clinical Terms) that merges two large-scale termi-
nologies—the Read codes and the SNOMED Reference terminologies developed by the College
of American Pathologists [15]. In particular, recording practices with these terminologies vary
substantially across healthcare settings depending on the purpose for which the data are being
collected. As a result, a huge number of health-related variables (codes) often turn up to
describe the conditions of a patient across multiple data points. This presents a big methodo-
logical challenge for identifying patients from electronic health records, as the high dimension-
ality of health-related features makes the classical statistical framework no longer feasible due
to the curse of dimensionality [10,11][16][17]. Thus, to reliably distinguish RA patients from
electronic health records, the key is to identify the most predictive RA code patterns buried in
the electronic health records.
In this study, we aim to develop a robust, valid and cost-effective method of identifying the
most informative predictors to detect RA patients from primary care electronic health records.
Different from a purely knowledge driven and deterministic approach, in this study, we pro-
pose to use data-driven method, which were initially used in the computing and retail indus-
tries (e.g., looking at shopping patterns for marketing) [18], to identify patterns within the
patient’s pathway of care to improve the accuracy of identification of those with RA from the
primary care record. We link primary and secondary care electronic patient records, and iden-
tify patients with RA in the primary care dataset while using the secondary care diagnosis as
the gold standard. Then we compare our data-driven methodology with two other existing
expert knowledge based methods. If the data driven method performs as well as expert opinion,
then it could provide a rapid and cost-effective way to reliably identify people with a health
condition, especially where knowledge-driven algorithms do not already exist. Thus, the overall
aim of this study was to develop an algorithm to define RA from primary care records using
data driven method.
Data-Driven Approach to Disease Phenotyping
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Methods
Dataset Preparations
The Farr Institute of Health Informatics Research comprises four centres distributed across the
UK. One of the nodes, CIPHER (Centre for Improvement in Population Health through
E-Records), brings together routine health data using the Secure Anonymised Information
Linkage (SAIL) databank [19], which anonymously links a wide range of person-based data
employing a unique personal identifier [20]. In this study the primary care general practice
(GP) records were linked with the local rheumatology secondary care clinical system. The GP
system uses Read codes, which are 5-digit codes that relate to diagnosis, medication and pro-
cess of care.
The structure of Read codes allows almost anything to be coded in the patient EHRs, such
as occupation; social circumstances; ethnicity and religion; clinical signs, symptoms and obser-
vations; laboratory tests and results; diagnoses; medications; a variety of administrative items.
Read terms are organised by Chapters, such as Chapters 1 to 9 about history, examination, pro-
cedures and administration, Chapters A to U about conditions, diagnoses and injuries, and
Chapters a to s about medications.
The secondary care dataset used in this study is from the clinical system—Cellma [21]
which has been used in the rheumatology departments of local hospitals in Abertawe Bro Mor-
gannwg University (ABMU—Swansea and Bridgend areas) and Cardiff and Vale University
Health Board (CVUHB). This commercial system uses SNOMED-CT to code diagnosis and
medications [22] as well as recording clinical data entered by rheumatologists at the point of
capture. The Cellma systems were available in the ABMU region fromMarch 2009 until Octo-
ber 2012, and in Cardiff from October 2013 to July 2014. Hospital admissions data for the
whole population of Wales is available in the SAIL databank, along with data from all general
practices in the ABMU region and 50% of general practices in the Cardiff region.
There were 2,238,360 patients over the age of 16 in the GP database contained in the SAIL
databank between the years 1999–2013. Linking the general practice and Cellma databases
gave an overlap of 20,667 people (15,459 from ABMU for 2009–2012 and 5,208 from Cardiff
for 2013–2014). The proportion of patients with a diagnosis of RA, according to specialist
rheumatologist consultants, recorded in Cellma (used as the gold standard diagnosis) was 17%
(n = 2,588 overall, 2,029 in the ABMU region and 559 in the Cardiff region).
Analysis Methods
Development of the data driven algorithm. Due to the higher number of patients with
RA in ABMU, this area was used to develop the algorithm as outlined below. Then the Cardiff
dataset was used as an independent population to validate the algorithm.
Phase 1: Preliminary selection of predictors: Due to the large number of codes available in
the UK primary care system, a preliminary selection of codes associated with RA was needed.
This involved examination of the relative frequencies of raw Read codes in those with gold
standard Cellma diagnosis of RA (cases) versus all those without RA (controls), which is
defined as follows
rFeqðxÞ ¼ pðRAjxÞ  pðnonRAjxÞ
where p(RA|x) = Nx.1/N and p(nonRA|x) = Nx.2/N are the prior probabilities of the RA and
non-RA cases respectively given the Read code x with Nx.1 cases of RA and Nx.2 cases of non-
RA among all N patients. In ranking the Read codes, the deﬁned relative frequency allows
important but infrequent Read codes to be identiﬁed. For example, the code for ‘swollen hand’
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may be rare in the entire database but 10 times more prevalent in RA patients. All the Read
codes with a higher relative frequency in cases versus controls were selected as initial predictor
variables. However, in this phase, the proposed relative frequency is a univariate metric only
used to measure the signiﬁcance of a single risk factor, without considering the interactions
between different factors.
Phase 2: Reduction of predictors through aggregation and wrapper approach: In this
phase, in order to select important subset of variables and taking into account the interactions
among variables, a feature selection wrapper approach was employed to perform feature selec-
tion and classification tasks simultaneously. Random Forest was used to rank the importance
of individual predictors and select key ones. Random Forest is an ensemble machine learning
classifier consisting of many local classification and regression tree classifiers [23]. In our
study, we used the Random Forest Gini impurity metric to rank the Read codes according to
which were most useful in correctly classifying cases versus controls. The Gini quantity gives
an indication of how strong the overall discriminative ability of a particular variable was for the
classification problem under study. Importantly, the “grouping property” of sub-trees [24]
enables the Random Forest to adeptly deal with correlation and interaction among variables.
Emerging evidence has shown that ranked variables considering the correlation and interaction
effects lead to a vast improvement for construction of a compact classification model [25]. The
Random Forest method selects two thirds of the data to construct each of the trees and then
employs the remaining one third of the data to estimate how many people are misclassified.
For example, one tree might be: If code for RA and code for methotrexate are present then iden-
tify these records as RA (case). Then the final one third split data can be used to see how often
this tree correctly classifies a person. It performs this for all trees and then, generates a list of
predictors ordered by their importance.
After ranking, an aggregation method was used to aggregate these selected Read codes if
they were similar to others in the database. For example, some medication Read codes, such as
those related to vitamin D prescription at a specific dose, were found among the list of selected
predictors. Read codes for vitamin D at differing doses (perhaps less frequently prescribed but
still valid predictors) can then be selected and examined to see if they improve the number of
people correctly classified. This means that the list of initial predictors acts like a list of ‘seeds’
to identify similar variables in the database. The variables sharing the same condition can be
further aggregated into one variable (e.g., grouping codes for laboratory tests that are normally
performed together, such as Read codes for white blood cell count to include basophil count,
lymphocyte count, eosinophil count, neutrophil count, and monocyte count). Although the
Random Forest method constructed numerous possible trees that perform well in selecting
important predictors to classify patients as either RA or non-RA, it is a “black-box”method in
nature, as it is difficult to induce the transparent classification rules and interpret the predic-
tions made by the model.
Phase 3: Classification rule induction: During this phase, the C5.0 decision tree (an
improved version of C4.5) [26] was used to automatically create ‘if-then’ rules using the aggre-
gated and selected predictors from the previous phases. Distinct from other machine learning
techniques, decision trees integrate the functions of the classification and feature selection
in one model structure. The C5.0 decision tree method uses a single tree/model to classify
patients, while the ‘if-then’ statements generated by a tree define a unique route to one terminal
node (RA or not RA) for any samples. For example, if a diagnosis of PsA (Psoriatic Arthritis)
was recorded, then the result would be ‘not RA’. If there was no diagnosis of PsA, then the algo-
rithm would advance to the next section of the tree. Each branch gives a single rule. This hierar-
chical structure leads to many rules sharing the same initial conditions, which constructs an
algorithm of identifying RA.
Data-Driven Approach to Disease Phenotyping
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Validation of the algorithm. The algorithm was then applied to two datasets: (a) the inde-
pendent Cardiff dataset of patients with a GP and secondary care rheumatology record, to eval-
uate performance at classifying RA among those attending a rheumatology clinic; and (b) all
475,580 people in the GP system and resident within the ABMU area during the period March
2009 to October 2012 (this is the period when there are valid diagnosis of conditions within the
ABMU Cellma) and aged 16+ during this time period. The performance of the algorithm in
the Cardiff dataset was assessed by calculating the sensitivity, specificity and positive predictive
value and compared with the performance of two existing algorithms which were generated
based on expert clinical opinion. These two existing algorithms were (1) the Quality and Out-
comes Framework (QOF) definition [13], and (2) the algorithm published by Thomas et al.
[12], which was developed on data from GP systems in England and so comparable to data sys-
tems in Wales. (The codes used by the QOF criteria and Thomas et al’s method in this study
can be found in the S1 Table). In terms of dataset (b) we reported sensitivity, specificity and
positive predictive value using a best case/worst case scenario analysis (Tables 1, 2 and 3). We
also examined the prevalence of RA over time using these algorithms in dataset (b) to confirm
that estimates were within the range expected from the literature.
Statistical analysis. The algorithm implementation, parameter tuning and performance
evaluation were all performed using R language in RStudio version 3.0.2 [27] with the packages
of ‘randomForest’ for RF [28], and ‘C50’ for C5.0 trees [29]. The performance of the algorithm
was assessed in terms of the sensitivity, specificity and positive predictive value.
Results
Algorithm Development
1. Phase 1: 900 predictor codes were identified from 43,100 potential Read codes. These
included different codes identifying, for example, the same medication but at varying doses
or varying administration methods (tablet, syrup, injection). These similar codes were
aggregated in the next phase.
2. Phase 2: The 900 predictors were reduced to 37 predictor code groups after the aggregation
phase. The 37 predictor code groups included groups of codes under a single name (for
example the code of ‘PREDNISOLONE’ would include all codes with Prednisolone listed as
the active ingredient, including the Read code for PREDNISOLONE 2.5 mg e/c tablets and
the code for PREDNISOLONE 5mg e/c tablets).
Table 1. The performance of data mining algorithm given worst case/best case assumptions.
Outpatient data (Cellma-
ABMU)
RA Not RA No data
GP data RA 1323 396 2560
Not RA 265 10084 459727
No data 138 1087
Worst case*: Sensitivity 80%,
Speciﬁcity 99%, Positive
predictive value 30%
Best case**: Sensitivity 93%,
Speciﬁcity 99%, Positive
predictive value 90.7%
*Worst case: no record in outpatients signiﬁes not RA.
**Best case: no record in outpatients signiﬁes patient with RA treated elsewhere.
doi:10.1371/journal.pone.0154515.t001
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3. Phase 3: A C5.0 decision tree was generated to identify RA patients. The C5.0 tree further
reduced the 37 predictor code groups to 8 predictor code groups. The decision tree method
helps to remove codes which cluster with other more predictive codes, accounting for
covariance and allowing the simplest model to be identified with the highest positive predic-
tive value in the Welsh population (see Fig 1). The 8 predictor code groups for the Welsh
population were: (1) RA codes as defined in the NHS QOF indictor set, (2) a group of codes
indicating strength of evidence for RA (including codes for seropositive or erosive RA and
codes for systemic manifestations of RA, see Table 4 for details), (3) a group of psoriatic
arthritis Read codes used to exclude RA; (4) an additional group of alternative diagnosis
codes for arthropathies other than RA or PsA also used to exclude RA as a diagnosis, (5)
prednisolone (at all different dosage), (6) methotrexate (all Disease-Modifying Antirheu-
matic Drugs (DMARD) with the active ingredient listed as methotrexate), (7) sulphasala-
zine and (8) leflunomide.
The decision rules with these predictor codes were induced as shown in Fig 1.
Algorithm Validation
Secondary care/GP overlap population in Cardiff. The population used for the valida-
tion (Cardiff-Cellma) had 27% prevalence of RA. The data driven algorithm gave a PPV:
85.6%, specificity: 94.6%, sensitivity: 86.2% and overall accuracy of 92.29%. This compared
with the QOF criteria alone (which is included within the data driven algorithm) which gave
PPV: 83%, specificity: 93.2%, sensitivity: 89.1% and accuracy: 92%. The Thomas et al’s method
gave PPV: 78.5%, specificity: 91.1%, sensitivity: 86.2% and accuracy: 89.8%.
Table 2. The performance of QOF criteria given worst case/best case assumptions.
Outpatient data(Cellma-
ABMU)
RA Not RA No data
GP data RA 1377 513 2851
Not RA 211 9967 459436
No data 138 1087
Worst case: Sensitivity 86.7%,
Speciﬁcity 99%, Positive
predictive value 29%
Best case: Sensitivity 95%,
Speciﬁcity 99%, Positive
predictive value 89%
doi:10.1371/journal.pone.0154515.t002
Table 3. The performance of expert knowledge driven algorithm given worst case/best case
assumptions.
Outpatient data(Cellma-
ABMU)
RA Not RA No data
GP data RA 1333 570 2139
Not RA 255 9910 460148
No data 138 1087
Worst case: Sensitivity 83.9%,
Speciﬁcity 99%, Positive
predictive value 28%
Best case: Sensitivity 94.2%,
Speciﬁcity 99%, Positive
predictive value 88%
doi:10.1371/journal.pone.0154515.t003
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Primary care population. Of the 475,580 people over 16 years old in the GP system in the
ABMU area, the algorithm would have classified 4,279 (0.9%) as having RA, which is consis-
tent with an existing study of estimated prevalence of RA across the UK population (0.8–0.9%)
[1]. Of the 4,279 people, 1,719 (40%) were found in the secondary care rheumatology system
and 1,323 (77%) were confirmed as having RA by the rheumatologist. However, 2,560 (60%) of
all the RA cases in the GP data were not found in the secondary care system. This could be
because (a) they did not have RA, (b) they are treated outside the ABMU area, such as else-
where in Wales or in England, (c) they are new cases waiting for a referral to the rheumatolo-
gist, or (d) they are old cases and no longer regularly seeing a rheumatologist or did not see a
rheumatologist in the time period for which we have data. If we assume a worst case scenario,
that none of the 2,560 cases have RA then this would give a prevalence of RA of 0.33%, a PPV:
30.9%, specificity: 99%, sensitivity 83%. If we assume a best case scenario, that all of the 2,560
cases did have RA but were treated by a rheumatologist outside the area then this estimate
would give a RA prevalence of 0.93%, with PPV: 91.3%, specificity: 99.9%, and sensitivity 94%.
Plotting the prevalence of RA within the ABMU region over time (Fig 2) shows that the data-
driven model and QOF algorithm produced comparable results, while the Thomas et al criteria
gave a lower prevalence for the region.
Fig 1. RA phenotyping model: (Left) C5.0 decision tree. The value of a variable is the number of its occurrence. At each final node, RA = 1 indicates
classification for positive RA and RA = 0 negative classified for RA. (Right) Decision rules generated from the C5.0 decision tree.
doi:10.1371/journal.pone.0154515.g001
Data-Driven Approach to Disease Phenotyping
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Table 4. Algorithm code definitions.
Predictor Description
RARTH_COD Rheumatoid Arthritis codes as deﬁned in the NHS Wales QOF Rheumatoid
Arthritis Indicator Set (RA Indicator Set NHS QOF Wales, 2014)
INTENSITY_RA A categorical variable with 5 levels, inspired in the reasoning on Thomas et al
(2008) work to deﬁne intensity of rheumatoid conditions: Class 1 is the most
severe diagnosis of rheumatoid arthritis and includes sero-positive rheumatoid
arthritis. Class 2 contains codes related to classiﬁcation of rheumatoid arthritis.
Class 3 contains conditions that are related to rheumatoid arthritis, such as
rheumatoid nodule. Class 4 identiﬁes patients that have sero-negetive
rheumatoid arthritis. The ﬁnal class is class 9 and identiﬁes patients who do not
have any history of rheumatoid arthritis.
ALTERNATIVE_RA Alternative arthropathy Read codes inspired in the reasoning in Thomas et al
(2008).
PSORIATIC_CD Psoriatic Arthritis Read codes
PREDNISOLONE Read codes related to different dosage of Prednisolone. Prednisolone is an
corticosteroid drug for controlling a local ﬂare in a joint, which is used effectively
in combination with other drugs (Ter Wee et al., 2014).
METHOTREXATE_CD Disease-modifying Antirheumatic Drugs (DMARDs) grouped by their active
ingredient- methotrexate,
SULPHASALAZINE_CD DMARDs grouped by their active ingredient-sulphasalazine
LEFLUNOMIDE_CD DMARDs grouped by their active ingredient-leﬂunomide
doi:10.1371/journal.pone.0154515.t004
Fig 2. Prevalence of RA for 2000–2010 in the ABMU region, Wales, UK.
doi:10.1371/journal.pone.0154515.g002
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Discussion
EHRs have been considered as an essential component in delivering high quality healthcare.
They provide enormous benefits not only for patient care, but also, when linked with other
sources of health-related records, for public health surveillance, measurement of outcomes and
a wide variety of research studies [16][17][30][31]. However, it is recognised that there are
large variations in the accuracy and completeness of the clinical information stored in primary
care electronic patient records [32][33]. Issues in using primary care electronic patient data
include: the codes are not robust enough; data curation was not performed resulting in a dis-
connection between data elements in the record and the patient's clinical status; and clinicians
may fail to enter codes properly, particularly where these relate to conditions diagnosed pre-
dominantly in secondary care settings. Therefore, it is unclear whether current primary care
electronic patient records capture clinical data adequately to reliably identify patients with a
particular condition for research purposes. In this study, we link primary care records with sec-
ondary care records, using the secondary care data acting as gold standard diagnosis for RA, to
develop a rapid data-driven method which can be used to accurately identify patients with RA
in primary care data codes. The developed algorithm performed as well as expert opinion and
the used QOF criteria in the UK. It demonstrates a method of deriving algorithms which can
be used for conditions without having QOF criteria and could be extended to develop algo-
rithms on systems that do not use Read codes. This data-driven method is based on the RA
patient pathway found in the health care system so can be used to derive algorithms specific for
that system. The findings demonstrate that for RA the QOF is a reliable and easy way of identi-
fying a condition. Therefore, when deriving algorithms, looking at the QOF criteria may be the
best place to start in the UK NHS. This finding may also be true in other countries where cod-
ing is linked to financial payments as there may be less variance around these codes [34]. How-
ever, the UK QOF criteria only apply to a limited number of conditions, while many countries
do not have robust coding linked to financial payment. In these cases, the data driven method
described here is a reliable way to identify codes related to RA.
The algorithm derived here relies on medication codes which improves the positive predic-
tive value, but reduces sensitivity and importantly will mainly select patients with a longer his-
tory of the RA condition (who will have had time to be given different types of medication)
and more severe disease (requiring more therapies). Previous studies have also reported that
adding codes for DMARDs from administration ICD billing data increases positive predictive
value in classifying RA patients, but decreases sensitivity [35][36]. Therefore, medication codes
can feature highly in a prevalence algorithm but an incidence algorithm may need to focus
more strongly on tests/procedures and ensuring no alternative diagnosis. Thus, distinct algo-
rithms to define prevalent and incident cases may be required.
This study offers several advantages. 1) It provides a novel way of automatically selecting
the most informative variables for RA diagnosis from a large number of coded data elements.
This can bring benefits in health informatics, for example, reducing the costs from many
aspects, such as model construction, data usages; using only the most informative variables can
also simplify the problem and speed up solutions; by selecting only the most informative vari-
ables, it is feasible to employ a particular classification model due to the challenge of curse of
dimensionality; in addition, discarding the irrelevant features can clean data and remove the
noises to significantly improve the generalisation performance by avoiding over-fitting
dilemma. 2) It can be performed very rapidly and cost-effectively and is particularly useful in
situations where it is unclear what RA codes should be used in the case of heterogeneous or
complex conditions. 3) The proposed method uses real life patient pathways to classify RA
rather than idealised best practice. 4) The RA decision rules generated are easily understood by
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users and clinicians in practical applications. It is a transparent method, which gives objective
results and is repeatable, so that all data and the method constructed can themselves lead to
reproducible research (datasets and methods can be published to be independently analysed).
However, the method we used requires a gold standard in order to develop or train the
model. There has to be a ‘correctly diagnosed’ reference in order to detect the patterns that pre-
dict that reference. In health informatics research, a key limitation in any algorithm develop-
ment research is the lack of a population based gold standard and without this, obtaining a
good estimate of performance of models applied to the whole population is difficult. This is
illustrated by the broad range of possible performance statistics for our RA algorithm when
worst and best case scenarios are considered. In addition, this data-driven method is mainly
applicable when using coded clinical terms and may not be applicable to textual data from
notes and letters, as these will require prior interpretation in order to be able to detect patterns.
Regarding implications for future research and practice, while manual selection based meth-
ods may achieve good predictive performance in patient phenotype identification for specific
disease, they require significant interactions between domain experts and informaticians to cre-
ate algorithms for each disease, which significantly limits their ability to be expanded to differ-
ent disease phenotypes. The data-driven approach in this study aimed at identifying the most
informative clinical criteria from data independently of domain experts (and the subjectivity
associated with this) and thus offers great promise of generalisation and scalability to pheno-
type identification for RA and other rheumatic diseases.
The findings of this work demonstrate how machine learning methods can be utilized to
create reliable disease phenotypes in EHRs. This method may be particularly valuable for large
population-based research cohorts like UK Biobank [37][38], USA eMERGE network [39][40]
[41], to give simple algorithms with good performance that are transparent and easy to apply.
This paper has also compared the data-driven methods with the two existing RA algorithms
available for RA research using UK datasets, so offers a comparison of performance that can be
used by researchers to decide which algorithm is most appropriate to their research.
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